PBAC's latest decision on Insulin aspart: Recommended (2021). Considered for Treatment of diabetes mellitus. Truvelog is a biosimilar to the reference brand NovoRapid, indicated for use under the same circumstances as existing NovoRapid formulations.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2018
Submissions
2
2018 → 2021
Eligible population
Adult patients with diabetes mellitus using insulin glargine.
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Safety and efficacy
Key trials
GEMELLI 1 (EFC 15081)
Comparator
NovoRapid
Economic model
Cost-minimisation
ICER note
Cost-minimisation basis; no ICER calculated as biosimilar is equi-effective to reference brand.